Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Portrazza (necitumumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Nippon Kayaku

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR expression	Lung Non-Small Cell Squamous Cancer	EGFR expression	Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : C1	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : C1
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	trastuzumab + osimertinib + necitumumab Sensitive: C3 – Early Trials trastuzumab + osimertinib + necitumumab Sensitive : C3	trastuzumab + osimertinib + necitumumab Sensitive: C3 – Early Trials trastuzumab + osimertinib + necitumumab Sensitive : C3